You are now combining the idea of post-market product surveillance with adverse reactions, even though they are separated here. In the presentation, it says one example is strengthening post-market surveillance, and a final example is “more information available to the public about the basis on which decisions are taken, adverse drug reactions and product risks”. But it's essentially all the same people, you're saying.
On February 7th, 2007. See this statement in context.